Published on March 6, 2013 at 11:32 AM
In busy emergency departments, timely, appropriate disposition and treatment decisions are critical. Often these decisions are made with limited information and in the face of clinical uncertainty. Today’s methods for diagnosing AKI rely on repeated, delayed assessments of creatinine and urine output over time. A snapshot of creatinine upon presentation to the ED provides limited information to helpfully complement clinical judgment. When used at the point of care, the Alere Triage® NGAL test provides critical data that may help ED clinicians not only detect, but also rule out AKI early, informing appropriate treatment decisions.
Advance online publication of the study is available on the publisher’s website at: http://ccforum.com/content/17/1/R29/abstract
About the Alere Triage® NGAL Test
The Alere Triage® NGAL Test is a rapid, point-of-care immunoassay used with the Alere Triage® Meter for the quantitative determination of NGAL in EDTA anticoagulated whole blood or plasma specimens, and provides results in about 20 minutes. The test bears the CE Mark and is available for commercial use in Europe and other countries outside the United States.
By developing new capabilities in near-patient diagnosis, monitoring and health information technology, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology and diabetes. Alere is headquartered in Waltham, Massachusetts. For more information regarding Alere, please visit www.alere.com.